MEOBF - Mesoblast's COVID-19 Foray And Other News: The Good Bad And Ugly Of Biopharma
Mesoblast Gets FDA Go-Ahead for COVID 19 Treatment Application
Mesoblast Limited (MESO) announced that the US FDA has cleared its Investigational New Drug application for treating patients suffering from acute respiratory distress syndrome ((ARDS)) due to coronavirus infection using remestemcel-L. The company intends to use the intravenous infusions of its allogeneic mesenchymal stem cell ((MSC)) product.
Mesoblast reported that the drug candidate is being developed for treating different inflammatory conditions and is believed to work by down regulating the production of pro-inflammatory cytokines. The drug is also believed to increase the production of